```
 * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:20:55 ON 08 MAR 2006

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\10531237.str
```




```
chain nodes :
25  26  27  28
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23
24
chain bonds :
2-26  7-20  13-19  15-25  26-27  26-28
ring bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  8-9  9-10  11-12  11-16  12-13  13-14
 14-15  15-16  17-18  17-21  17-24  18-19  19-20  20-21  21-22  22-23  23-24
exact/norm bonds :
17-18  17-21  17-24  18-19  19-20  20-21  21-22  22-23  23-24  26-27  26-28
exact bonds :
2-26  7-20  13-19  15-25
normalized bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  8-9  9-10  11-12  11-16  12-13  13-14
 14-15  15-16
isolated ring systems :
containing 1 : 11 : 17 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:CLASS  26:CLASS  27:CLASS  28:CLASS



L1       STRUCTURE UPLOADED


page
```

```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 full
L3             1 SEA SSS FUL L1

=> file ca


=> s l3
L4             1 L3

=> d ibib abs fhitstr
```

L4 ANSWER 1 OF 1 CA COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 141:23527 CA
TITLE: Preparation of quinolinyl pyrrolopyrazoles as TGF-β signal transduction inhibitors
INVENTOR(S): Beight, Douglas Wade; Sawyer, Jason Scott; Yingling, Jonathan Michael
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046382	A1	20040610	WO 2003-US32747	20031110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501322	AA	20040610	CA 2003-2501322	20031110
AU 2003291643	A1	20040618	AU 2003-291643	20031110
BR 2003015337	A	20050816	BR 2003-15337	20031110
EP 1565471	A1	20050824	EP 2003-768531	20031110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006040983	A1	20060223	US 2005-531237	20050413
NO 2005003045	A	20050621	NO 2005-3045	20050621
PRIORITY APPLN. INFO.:			US 2002-428893P P	20021122
			WO 2003-US32747 W	20031110

GI

L4 ANSWER 1 OF 1 CA COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 1 OF 1 CA COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The title compds. I and II, useful in treating cancer in a patient, were prepared E.g., a multi-step synthesis of II, starting from 6-bromo-4-methylquinoline and Me 6-methylpyridine-2-carboxylate (prepns. given), was given. The compds. I and II inhibit the TGF-β type I receptor kinase domain with IC50 of <20 μM, while exhibiting less toxicity in vivo than structurally related compds. as disclosed in PCT/US02/11884. The pharmaceutical composition comprising the compound II is claimed.

IT 700874-72-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolinyl pyrrolopyrazoles as TGF-β signal transduction inhibitors)

RN 700874-72-2 CA
CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

10/531237

=> file marpat

=> s l1 full
FULL SEARCH INITIATED 14:21:44 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 86 TO ITERATE

100.0% PROCESSED 86 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L5 1 SEA SSS FUL L1

=> d ibib abs fqhit

L5 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 138:4598 MARPAT
TITLE: Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF-β signal transduction inhibitors
INVENTOR(S): Sawyer, Jason Scott; Beight, Douglas Wade; Ciapetti, Paola; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Goodson, Theodore, Jr.; Herron, David Kent; Li, Hong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Mort, Nicolas Anthony; Yingling, Jonathan Michael; Smith, Edward C. R.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; et al.
SOURCE: PCT Int. Appl., 305 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094833	A1	20021128	WO 2002-US11884	20020513
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2446820	AA	20021128	CA 2002-2446820	20020513
EP 1397364	A1	20040317	EP 2002-744115	20020513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002009939	A	20040330	BR 2002-9939	20020513
CN 1511157	A	20040707	CN 2002-810508	20020513
JP 2004535404	T2	20041125	JP 2002-591506	20020513
NZ 528525	A	20051028	NZ 2002-528525	20020513
ZA 2003008546	A	20050131	ZA 2003-8546	20031031
US 2004106604	A1	20040603	US 2003-477111	20031106
NO 2003005193	A	20031121	NO 2003-5193	20031121

PRIORITY APPLN. INFO.: US 2001-293464P 20010524
WO 2002-US11884 20020513

GI

L5 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN (Continued)



I II

AB Title compds. I [R1 = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R2 = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine-N-oxide, quinazoline, etc.; p = 1-8; R3 = H, alkyl, alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared For instance, 1-[[2-(6-Bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene]amino]pyrrolidin-2-one (preparation given) was treated with NaH in DMF at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had IC50 < 20.00 μM for the TGF-β type I receptor.

MSTR 1



G1 = 284



G2 = 93



L5 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN (Continued)

G3 = 346-4 348-2

G6 = CONH2
G27 = alkoxycarbonyl <containing 1-6 C>
G39 = C(O)
Patent location: claim 1
Note: or N-oxides
Note: and pharmaceutically acceptable salts, esters and prodrugs

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/531237

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\237.str



chain nodes :
11 20 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 18 19
chain bonds :
2-20 7-15 11-14 20-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 12-13 12-16 12-19 13-14
14-15 15-16 16-17 17-18 18-19
exact/norm bonds :
11-14 12-13 12-16 12-19 13-14 14-15 15-16 16-17 17-18 18-19 20-21
exact bonds :
2-20 7-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10
isolated ring systems :
containing 1 : 12 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:CLASS 21:CLASS

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l6 full
L8            14 SEA SSS FUL L6

=> file ca


=> s l8
L9             2 L8

=> d ibib abs fhitstr 1-2
```

L9 ANSWER 1 OF 2 CA COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 141:23527 CA
TITLE: Preparation of quinolinyl pyrrolopyrazoles as TGF-β signal transduction inhibitors
INVENTOR(S): Beight, Douglas Wade; Sawyer, Jason Scott; Yingling, Jonathan Michael
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048382	A1	20040610	WO 2003-US32747	20031110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501322	AA	20040610	CA 2003-2501322	20031110
AU 2003291643	A1	20040618	AU 2003-291643	20031110
BR 2003015337	A	20050816	BR 2003-15337	20031110
EP 1565471	A1	20050824	EP 2003-768531	20031110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006040983	A1	20060223	US 2005-531237	20050413
NO 2005003045	A	20050621	NO 2005-3045	20050621
PRIORITY APPLN. INFO.:			US 2002-428893P	P 20021122
			WO 2003-US32747	W 20031110

GI



I



II

AB The title compds. I and II, useful in treating cancer in a patient, were prepared E.g., a multi-step synthesis of II, starting from 6-bromo-4-methylquinoline and Me 6-methylpyridine-2-carboxylate (prepns. given), was given. The compds. I and II inhibit the TGF-β type I receptor kinase domain with IC50 of <20 μM, while exhibiting less toxicity in vivo than structurally related compds. as disclosed in PCT/US02/11884. The pharmaceutical composition comprising the compound II is claimed.

IT 700874-72-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolinyl pyrrolopyrazoles as TGF-β signal transduction inhibitors)

RN 700874-72-2 CA
CN 6-Quinolinecarboxamide, 4-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]- (9CI) (CA INDEX NAME)

L9 ANSWER 1 OF 2 CA COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 CA COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 138:4598 CA
TITLE: Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF-β signal transduction inhibitors
INVENTOR(S): Sawyer, Jason Scott; Beight, Douglas Wade; Ciapetti, Paola; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Goodson, Theodore, Jr.; Herron, David Kent; Li, Hong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Mort, Nicolas Anthony; Yingling, Jonathan Michael; Smith, Edward C. R.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; et al.
SOURCE: PCT Int. Appl., 305 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094833	A1	20021128	WO 2002-US11884	20020513
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2446820	AA	20021128	CA 2002-2446820	20020513
EP 1397364	A1	20040317	EP 2002-744115	20020513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002009939	A	20040330	BR 2002-9939	20020513
CN 1511157	A	20040707	CN 2002-810508	20020513
JP 2004535404	T2	20041125	JP 2002-591506	20020513
NZ 528525	A	20051028	NZ 2002-528525	20020513
ZA 2003008546	A	20050131	ZA 2003-8546	20031031
US 2004106604	A1	20040603	US 2003-477111	20031106
NO 2003005193	A	20031121	NO 2003-5193	20031121
PRIORITY APPLN. INFO.:			US 2001-293464P	P 20010524
			WO 2002-US11884	W 20020513

OTHER SOURCE(S): MARPAT 138:4598
GI

L9 ANSWER 2 OF 2 CA COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [R1 = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R2 = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine-N-oxide, quinazoline, etc.; p = 1-8; R3 = H, alkyl, alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared For instance, 1-[[2-(6-Bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene]amino]pyrrolidin-2-one (preparation given) was treated with NaH in DMF at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had IC50 < 20.00 μM for the TGF-β type I receptor.

IT 476475-43-1P, 4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxylic acid methyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF-β signal transduction inhibitors)

RN 476475-43-1 CA

CN 6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 CA COPYRIGHT 2006 ACS on STN (Continued)

10/531237

=> file marpat

=> s l6 full
L10 1 SEA SSS FUL L6

=> d ibib abs

L10 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 138:4598 MARPAT
TITLE: Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF-β signal transduction inhibitors
INVENTOR(S): Sawyer, Jason Scott; Beight, Douglas Wade; Ciapetti, Paola; Decollo, Todd Vincent; Godfrey, Alexander Glenn; Goodson, Theodore, Jr.; Herron, David Kent; Li, Hong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Mort, Nicolas Anthony; Yingling, Jonathan Michael; Smith, Edward C. R.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; et al.
SOURCE: PCT Int. Appl., 305 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094833	A1	20021128	WO 2002-US11884	20020513
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2446820	AA	20021128	CA 2002-2446820	20020513
EP 1397364	A1	20040317	EP 2002-744115	20020513
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002009939	A	20040330	BR 2002-9939	20020513
CN 1511157	A	20040707	CN 2002-810508	20020513
JP 2004535404	T2	20041125	JP 2002-591506	20020513
NZ 528525	A	20051028	NZ 2002-528525	20020513
ZA 2003008546	A	20050131	ZA 2003-8546	20031031
US 2004106604	A1	20040603	US 2003-477111	20031106
NO 2003005193	A	20031121	NO 2003-5193	20031121
PRIORITY APPLN. INFO.:			US 2001-293464P	20010524
			WO 2002-US11884	20020513

GI

Dbl Pat 10/477111



I II

AB Title compds. I [R1 = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R2 = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine-N-oxide, quinazoline, etc.; p = 1-8; R3 = H, alkyl, alkylhydroxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared For instance, 1-[[2-(6-Bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene]amino]pyrrolidin-2-one (preparation given) was treated with NaH in DMF at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had IC50 < 20.00 μM for the TGF-β type I receptor.
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/531237

```
=> d his

     (FILE 'HOME' ENTERED AT 14:20:55 ON 08 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 14:21:00 ON 08 MAR 2006
L1              STRUCTURE UPLOADED
L2            0 S L1 SAM
L3            1 S L1 FULL

     FILE 'CA' ENTERED AT 14:21:24 ON 08 MAR 2006
L4            1 S L3

     FILE 'MARPAT' ENTERED AT 14:21:40 ON 08 MAR 2006
L5            1 S L1 FULL

     FILE 'REGISTRY' ENTERED AT 14:22:01 ON 08 MAR 2006
L6              STRUCTURE UPLOADED
L7            0 S L6 SAM
L8           14 S L6 FULL

     FILE 'CA' ENTERED AT 14:23:10 ON 08 MAR 2006
L9            2 S L8

     FILE 'MARPAT' ENTERED AT 14:23:53 ON 08 MAR 2006
L10           1 S L6 FULL

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

STN INTERNATIONAL LOGOFF AT 14:24:46 ON 08 MAR 2006
```